Join Growin Stock Community!

Palvella therapeutics, inc.PVLA.US Overview

US StockHealthcare
(No presentation for PVLA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PVLA AI Insights

PVLA Overall Performance

PVLA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PVLA Recent Performance

-2.70%

Palvella therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PVLA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PVLA Key Information

PVLA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PVLA Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Price of PVLA

PVLA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PVLA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
41.31
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
66162.26%
Revenue Growth (YoY)
-103.92%
Profit Growth (YoY)
-103.92%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.96
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
41.31
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
66162.26%
Revenue Growth (YoY)
-103.92%
Profit Growth (YoY)
-103.92%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is PVLA's latest earnings report released?

    The most recent financial report for Palvella therapeutics, inc. (PVLA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PVLA's short-term business performance and financial health. For the latest updates on PVLA's earnings releases, visit this page regularly.

  • How much cash does PVLA have?

    At the end of the period, Palvella therapeutics, inc. (PVLA) held Total Cash and Cash Equivalents of 63.57M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PVLA's EPS continuing to grow?

    According to the past four quarterly reports, Palvella therapeutics, inc. (PVLA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PVLA?

    Palvella therapeutics, inc. (PVLA)'s Free Cash Flow (FCF) for the period is -7.88M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,835.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PVLA?

    The latest valuation data shows Palvella therapeutics, inc. (PVLA) has a Price-To-Earnings (PE) ratio of -27.52 and a Price/Earnings-To-Growth (PEG) ratio of -0.77. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.